GlassScriptPhysician profile
Michelle Durm
NPI 1518451814
$14,073.43
in general payments reported to CMS, 2019-2025
25 companies · $4,134 in 2025
The $4,134 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $1,431 · 2023: $2,517 · 2024: $5,259 · 2025: $4,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,944 · Consulting Fee: $1,799 · Travel and Lodging: $1,048 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $840 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,944.31 |
| Consulting Fee | $1,799.00 |
| Travel and Lodging | $1,048.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $840.00 |
| Education | $278.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,682.16 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,424.63 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,210.48 | 2021-2025 | |
| Janssen Biotech, INC. | $826.88 | 2021-2025 | Tremfya |
| Ucb, INC. | $819.94 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $588.29 | 2021-2025 | |
| Galderma Laboratories, L.P. | $512.40 | 2022-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $506.41 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $443.50 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $395.66 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Dermavant Sciences, INC. | $324.00 | 2023-2024 | Vtama |
| Lilly USA, LLC | $313.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.01 | 2023-2024 | Spevigo |
| Amgen INC. | $178.10 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $157.73 | 2023-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $96.64 | 2025 | Acthar |
| Genzyme Corporation | $89.73 | 2022-2025 | |
| Strata Skin Sciences, INC. | $56.29 | 2024-2025 | Xtrac |
| Biofrontera INC. | $42.95 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $35.70 | 2025 | Sofdra |
| Leo Pharma INC. | $35.14 | 2022 | |
| Convatec INC. | $27.26 | 2024 | |
| Journey Medical Corporation | $22.39 | 2024 | |
| Janssen Scientific Affairs, LLC | $21.73 | 2023 | Tremfya |
| Mayne Pharma Commercial LLC | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Durm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.